A Novel Somatic Mutation Implicates ATP6V0D1 in Proinsulin Processing.
hypoglycemia
pancreatic neuroendocrine tumors
proinsulin
proinsulin processing
whole exome sequencing
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
06 Jan 2023
06 Jan 2023
Historique:
received:
18
08
2022
entrez:
25
1
2023
pubmed:
26
1
2023
medline:
26
1
2023
Statut:
epublish
Résumé
Prohormone convertase 1/3 (PC1/3), encoded by protein convertase subtilisin kexin type 1 (PCSK1), converts inactive prohormones into biologically active peptides. Somatic mutations of insulinomas are associated with genetic defects interfering with control of insulin secretion from pancreatic beta cells. However, somatic mutations in proinsulinomas have not been described. We report a case of a proinsulinoma, with suppressed insulin and C-peptide levels. A 70-year-old woman presented with a 20-year history of "blackouts." During a 72-hour fast, blood glucose level dropped to 1.9 mmol/L with suppressed plasma insulin and C-peptide levels, but proinsulin levels were raised at 37 pmol/L (<10 pmol/L). Imaging revealed 3 distinct DOTATATE-avid pancreatic lesions. Laparoscopic spleen-preserving distal pancreatomy was performed. In view of discordant insulin, C-peptide, and proinsulin levels, whole exome sequencing analysis was performed on the tumor. In the somatic exome of the tumor, we found mutations in Appropriately suppressed insulin levels in the context of hypoglycemia do not always indicate the absence of a neuroendocrine islet cell tumor and proinsulin levels may be indicated to solidify the diagnosis. In the context of elevated proinsulin levels, low insulin and C-peptide levels might be explained by somatic mutations that likely implicate proinsulin processing within the tumor. Furthermore, we propose several mechanistic candidates, including
Identifiants
pubmed: 36694809
doi: 10.1210/jendso/bvac196
pii: bvac196
pmc: PMC9856271
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvac196Subventions
Organisme : Medical Research Council
ID : MR/R022259/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.
Références
J Vis Exp. 2011 Mar 26;(49):
pubmed: 21490570
N Engl J Med. 2013 Jan 31;368(5):486-7
pubmed: 23363521
J Cell Biol. 1986 Dec;103(6 Pt 1):2273-81
pubmed: 3536964
Pancreas. 2019 Jan;48(1):55-59
pubmed: 30451800
Database (Oxford). 2015 Sep 30;2015:
pubmed: 26424082
Cell Mol Life Sci. 2021 Mar;78(5):1957-1970
pubmed: 33146746
Clin Pediatr (Phila). 1988 Mar;27(3):148-51
pubmed: 3342599
Vitam Horm. 2014;95:35-62
pubmed: 24559913
J Clin Endocrinol Metab. 2009 Mar;94(3):709-28
pubmed: 19088155
Curr Opin Oncol. 2008 Jan;20(1):25-33
pubmed: 18043253
Gastrointest Tumors. 2019 Oct;6(3-4):64-70
pubmed: 31768350
Nature. 1988 May 5;333(6168):93-6
pubmed: 3283564
J Biol Chem. 1987 Aug 5;262(22):10712-7
pubmed: 2440873
Int J Biochem Cell Biol. 2003 Sep;35(9):1312-7
pubmed: 12798345
Epilepsia. 2006 Feb;47(2):452; author reply 452
pubmed: 16499782
J Gastrointest Surg. 2017 Aug;21(8):1335-1341
pubmed: 28510792
Endocr Rev. 2016 Aug;37(4):347-71
pubmed: 27187081
J Inherit Metab Dis. 2012 Jul;35(4):589-601
pubmed: 22231386
J Cell Sci. 2006 Nov 1;119(Pt 21):4531-40
pubmed: 17046993
Physiol Rev. 2022 Jan 1;102(1):155-208
pubmed: 34280055
Diabetes Obes Metab. 2018 Sep;20 Suppl 2:64-76
pubmed: 30230179
Trends Endocrinol Metab. 2010 Oct;21(10):599-609
pubmed: 20609596